Table 1 Current EZH2 inhibitors in clinical
Drug | Condition | Phase | Combined Drug |
|---|---|---|---|
Tazemetostat (Epizyme, US) | Maligant Rhabdoid Tumors, Solid Tumor, Epitheliod Sarcoma, Bladder Cancer, Prostate Cancer, Lymphoma, Urothelial Carcinoma | Approved | Abiraterone/prednisone, Placebo Omeprazole, Repaglinide Pembrolizumab, Enzalutamide Fluconazole, Doxorubicin |
GSK2816126 (Glaxosmithkline, UK) | Myeloma Solid Tumors Non-Hodgkin’s Lymphoma | I | – |
CPI-1205 (Constellation, US) | B-Cell Lymphom Prostate Cancer Advanced Solid Tumors | I/II | Ipilimumab Enzalutamide Abiraterone/prednisone |
SHR2554 (HengRui, China) | Lymphoma Breast cancer Prostate Cancer | I/II | SHR3680 SHR1701 SHR3680 |
PF-06821497 (Pfizer, US) | Small cell lung cancer Follicular Lymphoma, DLBCL Castration Resistant Prostate Cancer | I | – |